NFNathan Ford

Nathan Ford

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nathan Ford has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Conflict in the Indian Kashmir Valley II: psychosocial impact

    by Kaz de Jong, Saskia van de Kam, Nathan Ford, Kamalini Lokuge, Silke Fromm, Renate van Galen, Brigg Reilley, Rolf Kleber

    India and Pakistan have disputed ownership of the Kashmir Valley region for many years, resulting in high levels of exposure to violence among the civilian population of Kashmir (India). A survey was done as part of routine programme evaluation to assess confrontation with violence and its consequences on mental health, health service usage, and socio-economic functioning.


  • Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand

    by Nathan Ford, David Wilson, Gabriela Costa Chaves, Michel Lotrowska, Kannikar Kijtiwatchakul

    Brazil and Thailand are among few developing countries to achieve universal access to antiretroviral therapy. Three factors were critical to this success: legislation for free access to treatment; public sector capacity to manufacture medicines; and strong civil society action to support government initiatives to improve access. Many older antiretroviral drugs are not patented in either country and affordable generic versions are manufactured by local pharmaceutical institutes. Developing countries were not required to grant patents on medicines until 2005, but under US government threats of trade sanctions, Thailand and Brazil began doing so at least ten years prior to this date. Brazil has used price negotiations with multi-national pharmaceutical companies to lower the price of newer patented antiretrovirals. However, the prices obtained by this approach remain unaffordable. Thailand recently employed compulsory licensing for two antiretrovirals, obtaining substantial price reductions, both for generic and brand products. Following Thailand's example, Brazil has issued its first compulsory license. Middle-income countries are unable to pay the high prices of multinational pharmaceutical companies. By relying on negotiations with companies, Brazil pays up to four times more for some drugs compared with prices available internationally. Compulsory licensing has brought treatment with newer antiretrovirals within reach in Thailand, but has resulted in pressure from industry and the US government. An informed and engaged civil society is essential to support governments in putting health before trade.


  • Open Access

    The trauma of ongoing conflict and displacement in Chechnya: quantitative assessment of living conditions, and psychosocial and general health status among war displaced in Chechnya and Ingushetia

    by Kaz de Jong, Saskia van der Kam, Nathan Ford, Sally Hargreaves, Richard van Oosten, Debbie Cunningham, Gerry Boots, Elodie Andrault, Rolf Kleber

    Conflict in Chechnya has resulted in over a decade of violence, human rights abuses, criminality and poverty, and a steady flow of displaced seeking refuge throughout the region. At the beginning of 2004 MSF undertook quantitative surveys among the displaced populations in Chechnya and neighbouring Ingushetia.


  • Registration problems for antiretrovirals in Africa

    by Nathan Ford, Marta Darder


  • The role of civil society in protecting public health over commercial interests: lessons from Thailand

    by Nathan Ford, David Wilson, Onanong Bunjumnong, Tido von Schoen Angerer


  • Patents, Access to Medicines and the Role of Non-Governmental Organisations

    by Nathan Ford

    One-third of the world's population lacks access to the most basic essential drugs. For the destitute sick in the developing world, the price of medicines can determine whether they will be treated. Patents drive drug prices up, the resultant monopoly status allowing the producer to charge whatever price the market will bear. The World Trade Organization Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which provides 20 years' patent protection for pharmaceuticals, also includes safeguards such as compulsory licensing, to ensure that countries can override patents whenever they are a barrier to access to medicines. Intense lobbying from the multinational pharmaceutical industry and some Western governments, however, has frustrated the use of these safeguards. Experience from South Africa, Thailand, Kenya and Guatemala shows the enormous pressures countries face in implementing the TRIPS Agreement in a manner that protects public health and underscores the vital role played by civil society in defending the right to access affordable medicines.


  • Public health and company wealth

    by Nathan Ford

    Introduction Millions of people in the developing world are dying because they cannot access the medicines they need. This made international headlines during the World Trade Organisation's meeting in Seattle in December 1999.1 The high price of AIDS drugs became a banner of the world's iniquities: on one side of the globe, Western multinationals made billions of dollars; on the other side, millions of people suffered and died of treatable infectious diseases. For decades the pharmaceutical industry was the Golden Boy of Wall Street. By the end of the 1990s it began to acquire a new reputation, featuring as the villain of spy novels (like John Le Carre's The Constant Gardener2) and Hollywood blockbusters (like Mission Impossible II). The industry has responded to growing public criticism by reducing some drug prices for some countries. From company boardrooms, it might seem that many sacrifices have been made. But few patients in developing countries are aware of these efforts. Progress in reducing drug prices has depended mostly on market competition (which the industry, through lobbying on global trade rules, is trying to squash) and media attention (which is fickle and exhaustible).


  • Mortality, Violence and Lack of Access to Healthcare in the Democratic Republic of Congo

    by Michel Van Herp, Veronique Parqué, Edward Rackley, Nathan Ford

    The people of the Democratic Republic of Congo for decades have been living in a situation of chronic crisis. Violence, population displacement and the destruction of infrastructure and health services have devastated the health of the population. In 2001, Médicins Sans Frontières conducted a survey in five areas of western and central DRC to assess mortality, access to health‐care, vaccination coverage and exposure to violence. High mortality rates were found in front‐line zones, mainly due to malnutrition and infectious diseases. In Basankusu approximately 10 per cent of the total population and 25 per cent of the under‐five population had perished in the year before the survey. Humanitarian needs remain acute across the country, particularly near the front line. Infectious‐disease control and treatment are a priority, as is increasing access to health‐care. Humanitarian assistance must be increased considerably, especially in rural areas and zones that have been affected directly by conflict.


  • Trade concerns must not be allowed to set the public health agenda.

    by Nathan Ford, Ellen 'T Hoen, Martin McKee